FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 506 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning October 13, 2021 Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 News digest – naked mole-rats, junk food deals, ovarian cancer drug... July 4, 2020 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Load more HOT NEWS No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... How Living in Service to Others Helped Me Cope During Cancer EMA Recommends Extension of Therapeutic Indications for Ibrutinib Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive...
